Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir

INTRODUCTION: Glecaprevir/pibrentasvir is approved for treating chronic hepatitis C virus (HCV) genotypes (GT) 1–6. We evaluated real-world effectiveness, safety, and patient-reported outcomes of glecaprevir/pibrentasvir in underserved patient populations, focusing on persons who use drugs infected...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghemo, Alessio, Horsmans, Yves, Bourgeois, Stefan, Bondin, Mark, Gschwantler, Michael, Hofer, Harald, Semmo, Nasser, Negro, Francesco, Zhang, Zhenzhen, Marcinak, John, Veitsman, Ella, Hazzan, Rawi, Mimidis, Konstantinos, Goulis, Ioannis, Marques, Nuno, Flisiak, Robert, Mazur, Wlodzimierz, Roncero, Carlos, Marra, Fiona, Pageaux, Georges Philippe, Asselah, Tarik, Lampertico, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572930/
https://www.ncbi.nlm.nih.gov/pubmed/34125405
http://dx.doi.org/10.1007/s40121-021-00455-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572930/
https://www.ncbi.nlm.nih.gov/pubmed/34125405
http://dx.doi.org/10.1007/s40121-021-00455-1

Ejemplares similares